Cara Therapeutics (CARA)
$13.40 0.00 (0.00%)
9:16 EDT CARA Stock Quote Delayed 20 Minutes
Previous Close $13.40
Market Cap 453.92M
PE Ratio -8.59
Volume (Avg. Vol.) 1,492
Day's Range 13.40 - 13.40
52-Week Range 8.88 - 27.55
Dividend & Yield N/A (N/A)
CARA Stock Predictions, Articles, and Cara Therapeutics News
- From InvestorPlace
- From the Web
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
Tilray, Canopy Growth and Cara Therapeutics are just a handful of cannabis stocks with the potential to double in value in the foreseeable future.
Looking for the real gains among the marijuana stocks? The key is to focus on firms using cannabis in medicine. Here are three biotech stocks moving headfirst into cannabis medicine.
It's not a great reason in and of itself to buy CGC stock , but Canopy Growth does have an overlooked presence in the medical cannabis arena.
Investors have heard a ton about cannabis stocks and their ridiculous valuations. But Wall Street analysts say these pot stocks still have a lot of upside ahead.
With cannabis stocks on fire, medical marijuana is the place to be. Here is the latest scoop on these seven leading medicinal pot stock plays.
Putting in the work may pay off big for In 2018, setting up the clinical studies dominated Cara Therapeutics' activities. For 2019, the study results may drive Cara stock higher. stock
Growing pressure to take action against China's illicit drug production could make investors more interested in CARA stock, potentially causing Cara Therapeutics stock to rally.
Cara Therapeutics (CARA) shares were up more than 11% on Wednesday as the company received good news regarding its latest clinical trial.
3 Stocks to Watch on Wednesday: Square Inc (SQ), Cara Therapeutics Inc (CARA) and Healthcare Services Group, Inc. (HCSG)
Square (SQ) continues its breathtaking 2017 rally Wednesday, Cara Therapeutics (CARA) jumps on trial results and Healthcare Services Group (HCSG) scores a post-earnings bump.
Why Best Buy Co Inc (BBY), Abercrombie & Fitch Co. (ANF) and Cara Therapeutics Inc (CARA) Are 3 of Today’s Worst Stocks
Too bad for Cara Therapeutics (CARA), Abercrombie & Fitch (ANF) and Best Buy (BBY) owners -- the market doesn't do do-overs.
Why Pandora Media Inc (P), Cara Therapeutics Inc (CARA) and Micron Technology, Inc. (MU) Are 3 of Today’s Worst Stocks
Micron Technology (MU), Pandora (P) and Cara Therapeutics (CARA) all ended the trading week on a bearish foot, but for understandable reasons.
Cara Therapeutics (CARA) stock was hit hard on Friday following poor results in its Phase 2b trial of osteoarthritis oral drug CR845.
Cara Therapeutics (CARA) stock was flying high on Friday following good news from the U.S. Food and Drug Administration.
Why Sears Holdings Corp (SHLD), Cara Therapeutics Inc (CARA) and Exxon Mobil Corporation (XOM) Are 3 of Today’s Worst Stocks
Cara Therapeutics (CARA), Sears Holdings (SHLD) and Exxon Mobil (XOM) and the day and the week on a low note, though for understandable reasons.
From Talk Markets
From Seeking Alpha
Imagine Owning Cara Therapeutics (NASDAQ:CARA) And Wondering If The 43% Share Price Slide Is Justified
From Simply Wall St
It’s easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market – but in the process, they<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cara/cara-therapeutics/news/imagine-owning-cara-therapeutics-nasdaqcara-and-wondering-if-the-43-share-price-slide-is-justified/">Read More...</a></div>
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Navellier RatingsPowered by Portfolio Grader